Catalent, Inc. (CTLT)
USD 63.48
(0.0%)
USD 63.48
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -284 Million USD | -206.77% |
| 2023 | 266 Million USD | -89.13% |
| 2022 | 1.08 Billion USD | 13.06% |
| 2021 | 1.11 Billion USD | 61.76% |
| 2020 | 640.2 Million USD | 36.88% |
| 2019 | 499.8 Million USD | 2.87% |
| 2018 | 453.5 Million USD | 15.93% |
| 2017 | 372.2 Million USD | -0.65% |
| 2016 | 374 Million USD | 4.03% |
| 2015 | 358.3 Million USD | -7.02% |
| 2014 | 373.4 Million USD | -28.64% |
| 2013 | 309.9 Million USD | 0.65% |
| 2012 | 305.09 Million USD | 20.95% |
| 2011 | 275.6 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 105 Million USD | 100.8% |
| 2024 FY | - USD | 702.53% |
| 2024 Q3 | 107 Million USD | 2000.0% |
| 2024 Q4 | 290 Million USD | 176.19% |
| 2024 Q1 | -48 Million USD | -3583.33% |
| 2023 Q4 | -96 Million USD | -357.14% |
| 2023 Q3 | -21 Million USD | -108.79% |
| 2023 Q2 | 239 Million USD | 50.31% |
| 2023 FY | - USD | -89.13% |
| 2023 Q1 | 159 Million USD | -54.31% |
| 2022 Q3 | 312 Million USD | 20.0% |
| 2022 FY | - USD | 13.06% |
| 2022 Q1 | 218 Million USD | -14.51% |
| 2022 Q4 | 348 Million USD | 11.54% |
| 2022 Q2 | 260 Million USD | 19.27% |
| 2021 Q4 | 255 Million USD | 1.55% |
| 2021 FY | - USD | 61.76% |
| 2021 Q3 | 251.1 Million USD | 18.56% |
| 2021 Q1 | 163.9 Million USD | -20.4% |
| 2021 Q2 | 211.8 Million USD | 29.23% |
| 2020 FY | - USD | 36.88% |
| 2020 Q3 | 125.5 Million USD | -23.57% |
| 2020 Q2 | 164.2 Million USD | 87.66% |
| 2020 Q4 | 205.9 Million USD | 64.06% |
| 2020 Q1 | 87.5 Million USD | -23.45% |
| 2019 FY | - USD | 2.87% |
| 2019 Q1 | 81.9 Million USD | -37.58% |
| 2019 Q2 | 132.1 Million USD | 61.29% |
| 2019 Q3 | 135.2 Million USD | 2.35% |
| 2019 Q4 | 114.3 Million USD | -15.46% |
| 2018 Q1 | 72 Million USD | -29.96% |
| 2018 Q4 | 131.2 Million USD | 3.88% |
| 2018 Q3 | 126.3 Million USD | 17.38% |
| 2018 Q2 | 107.6 Million USD | 49.44% |
| 2018 FY | - USD | 15.93% |
| 2017 Q2 | 83.7 Million USD | 31.19% |
| 2017 Q3 | 103 Million USD | 23.06% |
| 2017 Q4 | 102.8 Million USD | -0.19% |
| 2017 FY | - USD | -0.65% |
| 2017 Q1 | 63.8 Million USD | -40.26% |
| 2016 FY | - USD | 4.03% |
| 2016 Q2 | 93.9 Million USD | 26.55% |
| 2016 Q4 | 106.8 Million USD | 56.14% |
| 2016 Q1 | 74.2 Million USD | -18.37% |
| 2016 Q3 | 68.4 Million USD | -27.16% |
| 2015 FY | - USD | -7.02% |
| 2015 Q4 | 90.9 Million USD | -12.93% |
| 2015 Q1 | 2.6 Million USD | -97.5% |
| 2015 Q3 | 104.4 Million USD | 45.81% |
| 2015 Q2 | 71.6 Million USD | 2653.85% |
| 2014 Q2 | 86.7 Million USD | 14.68% |
| 2014 FY | - USD | -28.64% |
| 2014 Q3 | 98.5 Million USD | 13.61% |
| 2014 Q1 | 75.6 Million USD | -35.55% |
| 2014 Q4 | 104.1 Million USD | 5.69% |
| 2013 Q3 | 84.5 Million USD | 5.23% |
| 2013 Q4 | 117.3 Million USD | 38.82% |
| 2013 FY | - USD | 0.65% |
| 2013 Q1 | 73 Million USD | 0.0% |
| 2013 Q2 | 80.3 Million USD | 10.0% |
| 2012 FY | - USD | 20.95% |
| 2011 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 500.78 Million USD | 156.711% |
| Bausch Health Companies Inc. | 2.88 Billion USD | 109.844% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 43.796% |
| Elanco Animal Health Incorporated | -224 Million USD | -26.786% |
| Perrigo Company plc | 646.2 Million USD | 143.949% |
| Teva Pharmaceutical Industries Limited | 4.33 Billion USD | 106.554% |
| Zoetis Inc. | 3.68 Billion USD | 107.707% |